Pablo Tebas
Director, Developmental Core · Penn Center for AIDS Research
Credentials: · · · ·
History
Research
Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV
New England Journal of Medicine · 2014 · First of 20 authors · 1,038 citations
Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption
New England Journal of Medicine · 2016 · 421 citations
The Journal of Infectious Diseases · 2011 · 415 citations
29 papers
23 papers
22 papers
20 papers
- JK
17 papers
15 papers
- ED
14 papers
14 papers
Grants
- 2007–2027
University of Pennsylvania HIV Clinical Trials Unit
National Institute of Allergy and Infectious Diseases · UM1
Contact PI · $31.8M · University of Pennsylvania
- 1999–2024
National Institute of Allergy and Infectious Diseases · P30
Project lead · $12.2M · University of Pennsylvania
- 2022
Engineering T Cells to Provide Durable Control of HIV-1 Replication
National Institute of Allergy and Infectious Diseases · U19
Project lead · $3.3M · University of Pennsylvania
- 2003–2010
A Resource for Biomedical Mass Spectrometry
National Center for Research Resources · P41
Project lead · $35K · Washington University
Clinical trials
- 2022–2025
- 2019–2027
CD4 CAR+ ZFN-modified T Cells in HIV Therapy
Principal investigator · Active not recruiting · Phase 1
University of Pennsylvania
- 2019–2022
Oritavancin for Staphylococcus Aureus Infections in Opioid Users
Principal investigator · Withdrawn · Phase 4
University of Pennsylvania
- 2019–2022
A Study of INO-A002 in Healthy Dengue Virus-naive Adults
Principal investigator · Completed · Phase 1
University of Pennsylvania